MD Anderson study shows why some brain cancers resist treatment

(University of Texas M. D. Anderson Cancer Center) Scientists at The University of Texas MD Anderson Cancer Center may have discovered why some brain cancer patients develop resistance to standard treatments including radiation and the chemotherapy agent temozolomide.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

CONCLUSIONS: This study establishes normative data for a model exploiting dogs with naturally occurring glioma, which can be used to test novel therapies prior to translation to human trials. Further work will focus on the effects of different therapies, including chemotherapy, radiation therapy, and immunotherapy. PMID: 30234401 [PubMed - as supplied by publisher]
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
Publication date: Available online 17 September 2018Source: International Journal of PharmaceuticsAuthor(s): Srishti Agarwal, Priyadharshni Muniyandi, Toru Maekawa, D. Sakthi KumarAbstractGlioblastoma multiforme (GBM), one of the most lethal Brain tumors, characterized by its high invasive nature and increased mortality rates forms a major bottleneck in transport of therapeutics across the Blood Brain Barrier (BBB). Matrix metalloproteinases (MMPs) are classified as enzymes, which are found to be up regulated in the Glioma tumor microenvironment and thus can be considered as a target for inhibition for curbing GBM. Many ch...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Standard-of-care treatment for patients with pleural mesothelioma may soon include Tumor Treating Fields (TTF), a novel therapy involving electric currents that disrupt cancer cell division and inhibit tumor growth. In the wake of recently released results from Novocure’s STELLAR phase II clinical trial, the U.S. Food and Drug Administration (FDA) is expected to approve the treatment within the next six months, giving mesothelioma patients another much-needed option. “At this point, it should be a relatively rapid approval process,” Dr. Eilon Kirson, chief science officer at Novocure, the oncology company...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Abstract PURPOSE: BRAF mutations are divided into functional classes based on signaling mechanism and kinase activity: V600-mutant kinase-activating monomers (class I), kinase-activating dimers (class II), and kinase-inactivating heterodimers (class III). The relationship between functional class and disease characteristics in BRAF-mutant non-small cell lung cancer (NSCLC) has not been fully explored. EXPERIMENTAL DESIGN: We performed a retrospective analysis of BRAF-mutant NSCLCs treated at two institutions from 2005-2017 to determine clinicopathologic characteristics, progression-free survival (PFS) on chem...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
ConclusionLS-SCLC patients without PCI had a  high risk of BM. High T stage, high NLR, early thoracic radiotherapy and fewer chemotherapy cycles were the risk factors of BM. Further research is needed to confirm the results.
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
ConclusionsWVI or WBRT+  primary boost (PB) is a sufficient irradiation field for localized intracranial germinoma, while patients with bifocal disease should undergo craniospinal irradiation (CSI), especially when treated with RT alone. CSF β-HCG is not a prognostic marker for intracranial germinomas. The treatment res ults of chemotherapy followed by reduced-dose RT are comparable to those of RT alone. IMRT is recommended for intracranial germinoma to improve the target volume accuracy and decrease the complications of RT.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
This article summarizes the latest clinical trials concerning the use of radiotherapy, chemotherapy, molecularly targeted therapies and immunotherapy in lung cancer patients, with particular consideration of brain lung cancer metastasis prevention. The literature search was undertaken via PubMed and EMBASE searches and relevant articles are included in this review. Expert Commentary: The recent data supports that EGFR-TKIs and ALK inhibitors are clinically relevant for first-line treatment to prevent and treat CNS metastases in molecularly-selected NSCLC patients. In the future, high hopes for the prevention of CNS metasta...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Authors: Chammas M, Saadeh F, Maaliki M, Assi H Abstract Treating adult low-grade gliomas (LGGs) is particularly challenging due to the highly infiltrative nature of this type of brain cancer. Although surgery, radiotherapy, and chemotherapy are the mainstay treatment modalities for LGGs, the optimal combination management plan for a particular patient based on individual symptoms and the risk of treatment-induced toxicity remains unclear. This review highlights the competency and limitations of standard treatment options while providing an essential therapeutic update regarding current clinical trials aimed at imp...
Source: Journal of Clinical Neurology - Category: Neurology Tags: J Clin Neurol Source Type: research
ConclusionsThe developed model to describe resistance suggests that the resistance to EGFR-inhibition seen in these xenografts is best described by assuming a small percentage of cells are resistant to treatment at baseline. This model suggests changes to dosing and dosing schedule may not prevent resistance to treatment developing, and that additional treatments would need to be used in combination to overcome resistance.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
In this study, we examined the impact of focused ultrasound (FUS) in combination with microbubbles on the transport of two relevant chemotherapy-based anticancer agents in breast cancer brain metastases at...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Tags: PNAS Plus Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Chemotherapy | Neurology | Study | Temodar | Texas University